全球帕金森综合征队列的病理与遗传学研究
该多中心回顾性尸检确诊横断面脑库研究纳入3353名捐献者,评估帕金森综合征的临床病理相关性、诊断准确性及遗传关联。运动障碍误诊率约10%至20%,痴呆伴帕金森综合征与路易体病理关联更强,GBA1变异携带者路易体负荷更高,病理诊断因祖先背景而异。
要点
- 运动障碍临床诊断误诊率约10%至20%。
- 痴呆伴帕金森综合征与路易体病理关联强于无痴呆帕金森病。
- GBA1变异携带者路易体负荷高于非携带者及LRRK2变异携带者。
核心结论
- 整合遗传与病理数据可提高诊断准确性,阿尔茨海默病共病理高发及祖先相关病理差异提示需生物学诊断工具。
研究设计与样本
- 多中心回顾性尸检确诊横断面脑库研究,纳入1985至2024年英国、美国、澳大利亚11个脑库的3353名捐献者。
主要发现
- 运动障碍误诊率约10%至20%。
- 痴呆伴帕金森综合征与路易体病理关联的OR为1.96(95%CI 1.30-3.04,P=7.2×10-4)。
- 745名神经正常对照中33名(4.4%)存在路易体病理。
- 1064例路易体病中426例(40.0%)存在阿尔茨海默病共病理。
- GBA1变异携带者路易体负荷高于非携带者(OR 1.94,95%CI 1.24-3.03,P=.01)及LRRK2变异携带者(OR 7.44,95%CI 2.16-25.64,P=.01)。
关键数值与推荐
- 南亚裔捐献者更易见进行性核上性麻痹病理,德系犹太裔更易见路易体病(χ22=35.5,P<.001),独立于GBA1和LRRK2变异状态。
临床怎么用
- 临床应警惕运动障碍误诊,对痴呆伴帕金森综合征考虑路易体病理可能,并关注阿尔茨海默病共病理。
- 遗传分层(如GBA1、LRRK2)与病理结合有助于未来治疗试验设计。
局限性
- 横断面脑库研究设计,可能存在选择偏倚,遗传数据仅限部分捐献者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Accurate diagnosis of neurodegenerative movement disorders is challenging because of a lack of in vivo biomarkers, overlapping clinical features, and a delay in the emergence of pathognomonic features. OBJECTIVE: To evaluate clinicopathological correlation, diagnostic accuracy, genetic association with pathology, and ancestry-related differences in a multiancestry brain bank cohort. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, retrospective, autopsy-confirmed cross-sectional brain bank study on donors enrolled between 1985 and 2024. Included were donors from 11 academic brain banks in the UK, US, and Australia. Among brain donors with available genetic data from participating brain banks, included were individuals with clinical diagnoses of Parkinson disease, Parkinson disease dementia, dementia with Lewy bodies (DLB), progressive supranuclear palsy, corticobasal syndrome, multiple system atrophy, or neurologically normal controls. EXPOSURES: Genetic variant carrier status and clinical diagnostic category. MAIN OUTCOMES AND MEASURES: Outcomes included clinical diagnostic accuracy, Lewy body and Alzheimer disease pathology burden, survival, association with genetic variants, and genetically inferred ancestry. RESULTS: Among 5648 brain donors with available genetic data, a total of 3353 eligible donors (mean [SD] age at death, 76.8 [10.6] years; 2072 male [61.8%]) were included. Misdiagnosis rates for movement disorders ranged approximately from 10% to 20%. Clinical diagnoses of dementia with parkinsonism (ie, Parkinson disease dementia and DLB) were more strongly associated with Lewy body pathology than Parkinson disease without dementia (odds ratio [OR], 1.96; 95% CI, 1.30-3.04; P = 7.2 × 10-4). Lewy pathology was identified in 33 of 745 of neurologically normal controls (4.4%). Alzheimer disease copathology was present in 426 of 1064 cases (40.0%) with Lewy body disease. Carriers of the GBA1 variant exhibited greater Lewy body burden compared with noncarriers (OR, 1.94; 95% CI, 1.24-3.03; P = .01) or carriers of the LRRK2 variant (OR, 7.44; 95% CI, 2.16-25.64; P = .01). Pathological diagnoses differed by ancestry, with South Asian donors more likely to have progressive supranuclear palsy pathology and Ashkenazi Jewish donors more likely to have Lewy body disease (χ22 = 35.5; P < .001), independent of GBA1 and LRRK2 variant status. CONCLUSIONS AND RELEVANCE: Findings of this cross-sectional brain bank study highlight the value of integrating genetic and pathological data to improve diagnostic accuracy. The high prevalence of Alzheimer disease copathology and ancestry-associated differences in pathology point to the need for biologically informed diagnostic tools. These results suggest supporting the integration of genetically and pathologically stratified approaches, correlating pathology with in vivo biomarkers, for future therapeutic trials.
引用
- Wu LY, du Toit T, Georgiades T, et al. Pathology and Genetics in a Global Cohort of Parkinsonian Disorders. JAMA Neurol. 2026. PMID: 42258190. doi:10.1001/jamaneurol.2026.1634
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。